Filing Details

Accession Number:
0001179110-15-005187
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-03-18 18:20:55
Reporting Period:
2015-03-16
Filing Date:
2015-03-18
Accepted Time:
2015-03-18 18:20:55
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1145460 Alere Inc. ALR In Vitro & In Vivo Diagnostic Substances (2835) 043565120
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1600843 Carla Flakne 51 Sawyer Road, Suite 200
Waltham MA 02453
Vp, Chief Accounting Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-03-16 5,000 $38.10 5,000 No 4 M Direct
Common Stock Acquisiton 2015-03-16 3,500 $39.78 8,500 No 4 M Direct
Common Stock Disposition 2015-03-16 8,500 $48.99 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Disposition 2015-03-16 5,000 $0.00 5,000 $38.10
Common Stock Employee Stock Option (Right to Buy) Disposition 2015-03-16 3,500 $0.00 3,500 $39.78
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2016-12-15 No 4 M Direct
0 2020-04-30 No 4 M Direct
Footnotes
  1. Represents same day exercise and sale of stock options.
  2. Option vested in four equal installments on 12/15/07, 12/15/08, 12/15/09 and 12/15/10.
  3. Option vested in four equal installments in 4/30/11, 4/30/12, 4/30/13 and 4/30/14.
  4. This derivative security does not have a price.
  5. The price reported is a weighted average price. These shares were sold in approximately 76 separate transactions at prices ranging from $48.95 to $49.085, inclusive. The reporting person hereby undertakes to provide to the SEC, the issuer or any stockholder of the issuer, upon request, the full information regarding the number of shares and prices at which the transaction was effected.